Kraków, Poland – 09 August 2016 – Selvita Inc., the US subsidiary of Selvita S.A., headquartered in Cambridge, MA, has initiated a medicinal chemistry collaboration with the University of California, San Francisco (UCSF). The project will be conducted with the Institute for Neurodegenerative Diseases at UCSF.
Within the scope of the project, Selvita will be responsible for the chemical synthesis, purification, structure determination, and purity analysis of small molecules for the treatment of neurodegenerative diseases. The project will focus on the synthesis of new derivatives, constituting potential new therapeutics with improved pharmacological properties. This project was preceded by a thorough evaluation and pilot projects involving medicinal chemistry as well as ADME projects, which Selvita successfully completed. The contract will be carried out from 2016 to 2019.
“We’re truly delighted that such renowned research institutions as the Institute for Neurodegenerative Diseases and the University of California have decided to collaborate with Selvita on this project. This is a great chance for us to show the potential of our scientists, as well as the expertise and capabilities we have as a company,” said Andrzej Nieradka, Business Development Manager at Selvita Inc., who is responsible for managing the collaboration.
Selvita’s San Francisco Bay Area office was founded in San Bruno, CA in September 2015 and is dedicated to the support of Selvita business partners on the West Coast of the US. The office is located at 1001 Bayhill Drive, San Bruno, California. UC Disclaimer
The information stated above was prepared by Selvita Inc. and reflects solely the opinion of the corporation. Nothing in this statement shall be construed to imply any support or endorsement of Selvita Inc., or any of its products, by the Regents of the University of California, its officers, agents, or employees.